Artificial intelligence chipmaker Cerebras, which competes with Nvidia (NVDA) and AMD (AMD), has confidentially filed for an ...

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study ...

AstraZeneca announced on Thursday that it plans to invest more than 100 billion yuan ($15 billion) in China by 2030 to expand its pharmaceutical manufacturing and research and development footprint.

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago. The US regulator has ...

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical develop ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

XLV gains, top S&P 500 winners/losers, and key earnings & deal news on AstraZeneca, CVS, Moderna & Lilly—read now.

WILMINGTON, DE — AstraZeneca began trading its ordinary shares on the New York Stock Exchange on Monday, February 2, 2026, marking a significant milestone as the global biopharmaceutical giant expands ...

AstraZeneca full-year earnings: can the pharma giant maintain oncology momentum? AstraZeneca is set to release its full-year 2025 (FY25) financial results on 10 February 2026, a milestone moment for ...

AstraZeneca shares started trading on Wall Street yesterday – fuelling fears that the British drugs giant could eventually quit the London stock market. Bosses hailed ‘an exciting new period’ for the ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...

Today, a brief rundown of news from The Food and Drug Administration and AstraZeneca, as well as updates from Acadia Pharmaceuticals and MeiraGTx that you may have missed.